Table 1.
Ethanol intakes, body weights, and locomotor activity for groups in Figs. 2 and 4 through 8
In the Treatment Group column, the number in parentheses is the n per group.
| Treatment Group | Alcohol Intake | Body Weight | Locomotor Activity |
|---|---|---|---|
| g/kg/day | g | crosses/5 min | |
| 1. CRF Dose Response on Social Interaction (Fig. 2) | |||
| CD Veh (7) | – | 336 ± 5 | 112 ± 8 |
| CD CRF-0.5 (9) | – | 324 ± 6 | 131 ± 7 |
| ED Veh (7) | 7.42 ± 0.24 | 328 ± 5 | 99 ± 7 |
| ED CRF-0.045 (8) | 7.87 ± 0.14 | 328 ± 6 | 100 ± 10 |
| ED CRF-0.15 (8) | 7.70 ± 0.19 | 331 ± 6 | 113 ± 13 |
| ED CRF-0.5 (8) | 7.76 ± 0.18 | 330 ± 7 | 96 ± 10 |
| NS | NS | NS | |
| 2. CRF Microinjections into the BLA, DRN, and d-BNST on Social Interaction (Fig. 4) | |||
| CD Veh (12) | – | 320 ± 9 | 88 ± 15 |
| ED Veh (10) | 7.08 ± 0.20 | 341 ± 5 | 83 ± 18 |
| ED BLA CRF (7) | 7.53 ± 0.06 | 330 ± 4 | 97 ± 7 |
| ED DRN CRF (8) | 7.36 ± 0.36 | 325 ± 8 | 69 ± 8 |
| ED d-BNST CRF (10) | 7.23 ± 0.27 | 302 ± 6 | 63 ± 7 |
| NS | NS | NS | |
| 3. CRF Microinjections into the v-BNST, PVN, and CA1-Hippocampus on Social Interaction (Fig. 5) | |||
| CD Veh (9) | – | 312 ± 11 | 95 ± 20 |
| ED Veh (10) | 7.56 ± 0.49 | 325 ± 6 | 92 ± 15 |
| ED V BNST CRF (8) | 8.56 ± 0.18 | 304 ± 12 | 72 ± 10 |
| ED PVN CRF (9) | 8.45 ± 0.21 | 292 ± 10 | 90 ± 12 |
| ED Hippo CRF (9) | 8.17 ± 0.18 | 340 ± 7 | 72 ± 10 |
| NS | NS | NS | |
| 4. CRF-Induced Sensitization of Anxiety Blockade by CRF-1 Receptor Antagonists (Fig. 6) | |||
| CD Veh (13) | – | 315 ± 9 | 91 ± 14 |
| ED Veh (22) | 7.47 ± 0.17 | 333 ± 7 | 94 ± 10 |
| ED CeA CRF (9) | 6.91 ± 0.24 | 321 ± 10 | 89 ± 12 |
| ED SSR i.p. CeA CRF (8) | 8.35 ± 0.22 | 317 ± 7 | 119 ± 11 |
| ED DRN CRF (8) | 8.52 ± 0.20 | 306 ± 8 | 94 ± 10 |
| ED CP i.p. DRN CRF (8) | 7.75 ± 0.19 | 315 ± 9 | 81 ± 13 |
| ED d-BNST CRF (8) | 7.32 ± 0.14 | 312 ± 11 | 77 ± 16 |
| ED SSR i.p. d-BNST CRF (8) | 7.24 ± 0.26 | 326 ± 5 | 80 ± 12 |
| NS | NS | NS | |
| 5. Urocortin-3 into CeA, DRN, and d-BNST on Social Interaction (Fig. 7) | |||
| CD Veh (8) | – | 306 ± 4 | 119 ± 10 |
| CD UCN-3 (8) | – | 319 ± 5 | 121 ± 10 |
| ED Veh (14) | 7.37 ± 0.18 | 323 ± 5 | 111 ± 8 |
| ED CeA UCN-3 (8) | 7.97 ± 0.28 | 327 ± 5 | 109 ± 4 |
| ED DRN UCN-3 (11) | 7.60 ± 0.26 | 328 ± 8 | 102 ± 8 |
| ED d-BNST UCN-3 (8) | 7.60 ± 0.20 | 306 ± 11 | 122 ± 7 |
| ED i.c.v. UCN-3 (9) | 7.90 ± 0.18 | 304 ± 9 | 116 ± 7 |
| NS | NS | NS | |
| 6. Blockade of Stress Sensitization by CRF-1 Antagonist into the CeA, DRN, or d-BNST (Fig. 8) | |||
| CD Veh (18) | – | 310 ± 7 | 127 ± 10 |
| CD Stress (10) | – | 298 ± 6 | 132 ± 10 |
| ED Veh (9) | 7.57 ± 0.32 | 314 ± 9 | 112 ± 17 |
| ED Stress Veh CeA (7) | 8.24 ± 0.19 | 295 ± 8 | 111 ± 16 |
| ED Stress SSR CeA (8) | 8.26 ± 0.21 | 303 ± 6 | 135 ± 16 |
| ED Stress Veh DRN (8) | 7.70 ± 0.30 | 312 ± 8 | 132 ± 11 |
| ED Stress SSR DRN (11) | 8.20 ± 0.25 | 309 ± 11 | 129 ± 13 |
| ED Stress Veh d-BNST (6) | 8.01 ± 0.24 | 300 ± 12 | 130 ± 12 |
| ED Stress SSR d-BNST (7) | 8.33 ± 0.24 | 285 ± 7 | 129 ± 6 |
| NS | NS | NS | |
N.S., no significant difference noted among the groups for any of the measures for each of the six experiments (1–6); Hippo, hippocampus; Veh, vehicle; SSR, SSR125543.